Indivior Pharmaceuticals Inc
INDV
NASDAQ
Healthcare
$39.80
-1.12%loss today
Market position
Market cap rank
#1413
of 2,614
1-day
-1.12%
1-month
+18.07%
6-month
+10.93%
YTD
+11.39%
1-year
+158.44%
5-year
+257.59%
Key figures
Market cap
$4.97B
P/E (live)
23.7
price ÷ annual EPS
P/E (reported)
21.4
FY 2025
EPS
$1.68
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
80.15%
FY 2025
Operating margin
21.39%
FY 2025
Net margin
16.95%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$4.64B
FY 2025
EV / EBITDA
15.27
FY 2025
EV / Sales
3.75
FY 2025
Price / book
-45.77
FY 2025
Price / sales
3.62
FY 2025
Earnings yield
4.68%
FY 2025
FCF yield
-2.07%
FY 2025
Debt / equity
-3.58
FY 2025
Current ratio
0.71
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$1.24B
Gross profit
$993M
Operating income
$265M
EBITDA
$304M
Net income
$210M
Diluted EPS
$1.64
Shares outstanding
125,000,000
Trading
Open
$40.14
Previous close
$40.25
Day range
$39.56 – $40.81
52-week range
$14.93 – $42.81
50-day avg
$37.73
200-day avg
$32.77
Volume
1,450,982
Avg volume
1,967,287
Beta
1.15
Price history
+158.44% over 1Y
Compare with peers
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Visit websiteCompany info
CEO
Joseph J. Ciaffoni
IPO date
Dec 29, 2014
Headquarters
North Chesterfield, VA, US
Country
Fundamentals are annual. Figures labeled with their fiscal year.
